糖尿病肾病大鼠肾组织内质网应激水平以及中药干预治疗的研究
发布时间:2018-12-15 05:23
【摘要】:目的:1.动物实验部分:探讨糖尿病肾病大鼠肾组织内质网应激相关分子GRP78,Caspase-12、CHOP水平及祛痰通络汤的干预治疗效果及机制.2.临床实验部分:临床观察祛痰通络汤对糖尿病肾病患者的疗效。方法:1.动物实验部分:糖尿病肾病模型的制备采用高糖高脂饲料喂养大鼠,并腹腔注射STZ的方法。随机分为正常对照组、模型组、祛痰通络汤组、四苯基丁酸组,祛痰通络汤组大鼠按2m L/100g剂量灌胃,4-PBA组大鼠按1g/kg的剂量每日灌胃,治疗8周。检测生化指标如糖化血红蛋白、血肌酐、尿素氮等指标,观察大鼠肾脏组织的病理改变;应用免疫组织化学和Western-blot检测糖尿病肾病大鼠肾组织内质网应激相关蛋白GRP78、Caspase-12、CHOP的表达.2.临床实验部分:84例糖尿病肾病Ⅲ-Ⅳ期痰瘀阻络证患者随机分为治疗组42例,对照组42例,干预2个月,观察患者尿白蛋白排出率(UAE)、尿素氮、肌酐、胱抑素C(Cys C)、糖化血红蛋白的变化。结果:动物实验部分1.模型组血糖、糖化血红蛋白水平明显升高,治疗组血糖、糖化血红蛋白水平较模型组明显下降(P0.05),祛痰通络汤组下降更明显(P0.05)。2.与对照组相比,糖尿病肾病大鼠模型组尿素氮、肌酐、胱抑素C水平明显升高(P0.05);与模型组相比,治疗组的尿素氮、肌酐、胱抑素C水平明显下降(P0.05),祛痰通络汤组治疗效果优于4-PBA组.3.治疗前,模型组及治疗组的24h尿蛋白定量无明显差别(P0.05),治疗4周、8周后,祛痰通络汤组24h尿蛋白量较模型组及治疗前均明显下降(P0.05).4.HE染色光镜观察可见对照组大鼠肾脏的肾小球结构正常,无毛细血管基底膜增厚,系膜细胞无增生,系膜区无增宽,肾小管结构正常;糖尿病肾病大鼠模型组肾脏肾小球明显肥大,基底膜明显增厚,肾小球的系膜细胞增生,系膜区增宽,部分肾小管上皮细胞出现肥大、空泡样变性;祛痰通络汤组及4-PBA组的肾脏病理改变较模型组明显减轻,祛痰通络汤组肾小球病变程度轻于4-PBA组.5.免疫组化染色:5.1免疫组化发现内质网分子伴侣GRP78在模型组的表达明显高于对照组,表明ERS在糖尿病肾肾病的肾组织中激活,祛痰通络汤降低GRP78蛋白表达,Western-blot的检测结果与免疫组化结果相一致。5.2应用Western-blot对Caspase-12、CHOP的蛋白表达水平研究,发现糖尿病肾病大鼠模型组Caspase-12、CHOP的蛋白表达水平明显升高(P0.05),与免疫组化结果结果一致,免疫组化发现,在模型组大鼠肾脏中的Caspase-12、CHOP的分布范围和表达强度明显高于对照组,祛痰通络汤降低蛋白表达水平及范围.临床实验部分1.祛痰通络汤改善糖尿病肾病患者的临床症状(P0.05)。2.祛痰通络汤治疗组临床综合疗效92.5%,明显优于对照组75%;治疗组的血清BUN、SCr、Cys C水平下降,疗效明显优于对照组(P0.05)。结论:1.糖尿病肾病大鼠模型组肾组织的内质网应激相关分子GRP78、Caspase12、CHOP升高,提示糖尿病肾病大鼠肾组织内质网应激激活。2.祛痰通络汤能够降低内质网应激相关分子GRP78、Caspase12、CHOP的表达,减轻肾脏病理学改变,延缓糖尿病肾病的进程。3.祛痰通络汤能够降低糖尿病肾病大鼠的血糖、血清肌酐、尿素氮,胱抑素C,减少尿蛋白排出,改善糖尿病肾病大鼠肾功能指标。4.祛痰通络汤能够改善糖尿病肾病患者临床症状,改善实验室检查指标,其总有效率达92.5%,明显优于对照组(75.0%)。
[Abstract]:Objective: 1. The experimental part of the animal: To study the effect and mechanism of the intervention of the related molecular GRP78, Caspase-12, CHOP, and the expectorant in the kidney of diabetic nephropathy rats. Clinical experiment part: The clinical observation of the effect of the phlegm-removing and collateral-dredging decoction on the patients with diabetic nephropathy. Method: 1. Animal experiment part: The preparation of diabetic nephropathy model adopts high-sugar high-fat feed to feed the rat, and the method of STZ is injected into the abdominal cavity. The rats were randomly divided into the normal control group, the model group, the phlegm-eliminating and collateral-dredging decoction group, the tetraphenylbutyrate group, the phlegm-eliminating and collateral-dredging decoction group, the rats were given intragastric administration at a dose of 2 m L/ 100 g, and the 4-PBA group rats were given intragastric administration at a dose of 1 g/ kg for 8 weeks. The expression of protein GRP78, Caspase-12 and CHOP in the renal tissue of rats with diabetic nephropathy was detected by immunohistochemistry and Western-blot. The clinical experiment part: 84 patients with type 鈪,
本文编号:2380059
[Abstract]:Objective: 1. The experimental part of the animal: To study the effect and mechanism of the intervention of the related molecular GRP78, Caspase-12, CHOP, and the expectorant in the kidney of diabetic nephropathy rats. Clinical experiment part: The clinical observation of the effect of the phlegm-removing and collateral-dredging decoction on the patients with diabetic nephropathy. Method: 1. Animal experiment part: The preparation of diabetic nephropathy model adopts high-sugar high-fat feed to feed the rat, and the method of STZ is injected into the abdominal cavity. The rats were randomly divided into the normal control group, the model group, the phlegm-eliminating and collateral-dredging decoction group, the tetraphenylbutyrate group, the phlegm-eliminating and collateral-dredging decoction group, the rats were given intragastric administration at a dose of 2 m L/ 100 g, and the 4-PBA group rats were given intragastric administration at a dose of 1 g/ kg for 8 weeks. The expression of protein GRP78, Caspase-12 and CHOP in the renal tissue of rats with diabetic nephropathy was detected by immunohistochemistry and Western-blot. The clinical experiment part: 84 patients with type 鈪,
本文编号:2380059
本文链接:https://www.wllwen.com/yixuelunwen/mjlw/2380059.html
最近更新
教材专著